Understanding the Value of Your Chief Compliance OfficerPharmaceutical Compliance Monitor May 8, 2013
George Breen, Chair of the firm's National Health Care and Life Sciences Practice Steering Committee, in the Washington, DC, office, and David Gibbons, an Associate in the Health Care and Life Sciences practice in the Washington, DC, office, co-wrote an article titled "Understanding the Value of Your Chief Compliance Officer."
Following is an excerpt:
One needs look no further than the evening news for examples of the government's continuing pursuit of pharmaceutical companies for alleged failures to ensure compliance with the law.
The U.S. Department of Justice (DOJ) has reported record-setting monetary settlements related to health care fraud cases and investigations brought against the pharmaceutical industry, with recoveries growing by the year. In FY 2012 alone, the DOJ said it had secured nearly $2 billion in connection with federal civil and criminal cases alleging violations of the federal False Claims Act (FCA) by pharmaceutical and medical device companies.